These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 24166456

  • 1. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S, Vaziri ND.
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B, Wu M, Cao A, Li H, Liu J.
    Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
    [Abstract] [Full Text] [Related]

  • 5. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J, Rodríguez-Borjabad C, Ibarretxe D, Heras M, Amigo N, Feliu A, Masana L, Plana N, DECOPIN Group.
    J Clin Lipidol; 2018 Jan; 12(1):211-218. PubMed ID: 29102496
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
    Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P.
    Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.
    Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, Scotti E, Boyadjian R, Kim J, Chamberlain BT, Tangirala RK, Jung ME, Fong L, Lee R, Young SG, Temel RE, Tontonoz P.
    Cell Metab; 2014 Nov 04; 20(5):910-918. PubMed ID: 25440061
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 04; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia.
    Zhang CP, Tian Y, Zhang M, Tuo QH, Chen JX, Liao DF.
    Med Hypotheses; 2016 Jan 04; 86():138-42. PubMed ID: 26601593
    [Abstract] [Full Text] [Related]

  • 14. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
    Zhang L, Reue K, Fong LG, Young SG, Tontonoz P.
    Arterioscler Thromb Vasc Biol; 2012 Nov 04; 32(11):2541-6. PubMed ID: 22936343
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of hepatic LDL receptor expression in experimental nephrosis.
    Vaziri ND, Liang KH.
    Kidney Int; 1996 Sep 04; 50(3):887-93. PubMed ID: 8872963
    [Abstract] [Full Text] [Related]

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 15; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 20. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB, Holla ØL, Cameron J, Berge KE, Leren TP.
    Clin Chim Acta; 2010 Feb 15; 411(3-4):229-33. PubMed ID: 19917273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.